Highest-materiality recent filing
Arrowhead Q3 revenue $75.3M; plozasiran Phase 3 hits endpoints; Madrigal license deal
Revenue $75.3M (up 171% YoY); net loss $194.3M ($1.36 diluted EPS) vs $175.2M ($1.26) prior year.
Arrowhead Q2 revenue $73.7M, net loss $0.93; REDEMPLO strong; $930M capital raise; Madrigal license
Q2 revenue $73.7M (down 86% YoY); net loss $132.7M ($0.93 diluted EPS) vs prior-year income $370.4M ($2.75 EPS).
Arrowhead Q1 revenue $264M; REDEMPLO launched; $930M financing closed
Revenue $264M (vs $2.5M YoY); net income $30.8M ($0.22 diluted EPS) vs loss $173M.
Arrowhead issues $700M zero-coupon convertible notes due 2032; enters capped call to reduce dilution
Arrowhead issued $700M 0.00% convertible senior notes due 2032; conversion price ~$87.07 per share.
Arrowhead prices upsized $625M zero-coupon convertible notes and $216.6M equity offering
Net proceeds of ~$681.3M from $700M (including over-allotment) of 0.00% convertible notes due 2032.
ARO-INHBE + tirzepatide (n=4) achieved -9.4% weight loss at week 16 vs -4.8% with tirzepatide alone; visceral fat -23.2% vs -7.4%.
Arrowhead FY2025 revenue $829M on milestones; FDA approves first drug REDEMPLO
Revenue $829.4M in FY2025, up from $3.6M, driven by Novartis and Sarepta milestone payments.
Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO for Familial Chylomicronemia Syndrome
REDEMPLO (plozasiran) approved by FDA as adjunct to diet to reduce triglycerides in adults with FCS.
Ionis sues Arrowhead for patent infringement over plozasiran, threatening FCS launch
Ionis filed complaint in Central District of California alleging Arrowhead's plozasiran infringes U.S. Patent No. 9,593,333.
Arrowhead files declaratory judgment suit against Ionis over '333 patent for plozasiran
Arrowhead filed a declaratory judgment action in Delaware against Ionis claiming the '333 patent is invalid and not infringed by plozasiran.
Arrowhead licenses ARO-SNCA to Novartis for $200M upfront, up to $2B milestones
Arrowhead receives $200M upfront; eligible for up to $2B in development, regulatory, sales milestones.
Arrowhead Q3 revenue $27.8M, net loss $1.26/sh; plozasiran PDUFA Nov 18, 2025
Revenue $27.8M (vs $0 YoY); net loss attributable $175.2M, or $1.26 diluted EPS (vs $1.38).
Arrowhead Q2 revenue $542.7M on Sarepta deal; plozasiran PDUFA Nov 18, 2025
Q2 revenue of $542.7M (vs $0 prior year) driven by $825M Sarepta licensing deal ($500M cash + $325M equity).
Arrowhead CFO Ken Myszkowski to retire May 13; Daniel Apel named new CFO
Ken Myszkowski will retire as CFO effective May 13, 2025, after 16 years; no disagreement cited.
Arrowhead Q1 net loss $173M; $825M Sarepta deal & plozasiran NDA accepted
Net loss of $173M ($1.39 diluted EPS), revenue $2.5M, operating loss $161.4M.
Arrowhead appoints Sarepta CEO Douglas Ingram as director
Douglas Ingram appointed to Arrowhead board effective Feb 6, 2025, per Investor Rights Agreement with Sarepta.
Arrowhead reports FY2024 net loss $599.5M; inks Sarepta deal, files plozasiran NDA
Net loss of $599.5M (-$5.00 diluted EPS) vs $205.3M loss (-$1.92) in FY2023.
Net loss of $170.8M ($1.38 diluted EPS) vs $102.9M ($0.96) a year ago; revenue nil vs $15.8M.
Arrowhead Q2 net loss $125.3M ($1.02/share) vs prior year net income $48.7M; revenue $0
Net loss of $125.3 million ($1.02 diluted loss per share) compared to net income of $48.7 million ($0.45 diluted EPS) in Q2 2023.
Revenue $3.55M vs $62.55M YoY; net loss $132.9M ($1.24 EPS) from $41.3M ($0.39 EPS) loss prior year.
Arrowhead prices 15.79M share offering at $28.50, expects net proceeds of $429.0M
Sales of 15,790,000 shares at $28.50/share; net proceeds ~$429.0M after discounts and expenses.
Arrowhead Pharma reports FY2023 net loss of $205M, pipeline advances
Revenue $240.7M vs $243.2M YoY; net loss $205.3M (EPS -$1.92) vs $176.1M (-$1.67).
Arrowhead Q3 net loss widens to $103M; revenue drops 51%; milestones from GSK and Takeda
Revenue $15.8M (down 51% YoY from $32.4M); net loss $102.9M (vs $72.0M loss); diluted EPS -$0.96 (vs -$0.68).
Arrowhead Q2 net income $48.7M ($0.45 diluted); milestones from Takeda, GSK, positive ARO-RAGE data
Revenue $146.3M, operating income $48.2M, net income $48.7M ($0.45 diluted), up from $44.4M ($0.41) in prior year.
Arrowhead Regains Full Rights to ARO-PNPLA3 After Janssen Terminates Collaboration
Janssen terminated the Research Collaboration and Option Agreement with Arrowhead effective April 7, 2023.
Arrowhead Pharma Q1 revenue $62.5M, net loss narrows to $0.39; sells olpasiran royalty for $250M
Revenue $62.5M vs $27.4M; net loss $41.3M ($0.39/share) improved from $62.9M ($0.60).
Arrowhead Pharmaceuticals raises ~$250M via equity offering of 7.8M shares through Jefferies
Entered Open Market Sale Agreement with Jefferies LLC to sell up to 7,807,620 shares of common stock.
Arrowhead Pharma reports FY22 revenue up but net loss widens to $172.7M; $250M royalty sale
Revenue $243.2M for FY22 (Sep 30 yr-end), up 76% from $138.3M in FY21.
Arrowhead sells olpasiran royalty rights to Royalty Pharma for up to $410M
Royalty Pharma pays $250M upfront for future royalties from Amgen on olpasiran.
Arrowhead Q3 FY2022 revenue $32.4M, net loss $72.0M; pipeline progresses
Q3 FY2022 revenue $32.4M (down 29% YoY); net loss $72.0M ($0.68 loss per share) vs $29.9M loss prior year.
Arrowhead Q2 FY2022 net income $44.4M on revenue $151.8M vs prior year loss
Revenue $151.8M for Q2 ended Mar 31, 2022, up from $32.8M YoY; net income $44.4M ($0.41 diluted EPS) vs net loss $26.8M ($0.26 loss) year ago.
Arrowhead forms JV with Vivo Capital for Greater China; licenses four RNAi cardiometabolic drugs
Vivo Capital provided $60M initial funding to Visirna Therapeutics, JV in which Arrowhead holds majority stake.
Arrowhead Q1 net loss widens to $0.60/share; GSK licenses NASH candidate
Net loss of $62.9M ($0.60 diluted EPS) vs $20.7M ($0.20) in prior year quarter.
On June 12, 2026, the Board of Directors of Arrowhead Pharmaceuticals, Inc. (the “Company”) appointed Dr. Matt Cohen, M.D., M.B.A., as a director of the Company, effective June 12, 2026.
Ken Myszkowski notified Arrowhead Pharmaceuticals, Inc. (the “Company”) of his decision to retire as Chief Financial Officer of the Company, effective as of May 13, 2025
the Company determined that it would appoint Daniel Apel to serve as Chief Financial Officer of the Company
On February 5, 2025, the Board of Directors of Arrowhead Pharmaceuticals, Inc. (the “Company”) appointed Douglas Ingram as a director of the Company, effective February 6, 2025.
Appointment of Hongbo Lu as a Director
On February 21, 2024, the Board of Directors of Arrowhead Pharmaceuticals, Inc. (the “Company”) announced that it would increase the size of the Company's board of directors ("Board") from seven to eight members and appoint Hongbo Lu, Ph.D., as an independent director of the Company, effective April 1, 2024.
Javier San Martin, M.D., the Chief Medical Officer of Arrowhead Pharmaceuticals, Inc. (the “Company”), will be leaving the Company, effective as of February 1, 2024.
Bruce Given, M.D., who previously served as the Company's Chief Operating Officer and head of Research and Development until his retirement on May 1, 2020, will assist the Company in the orderly transition of Dr. San Martin's departure in Dr. Given’s new role as Chief Medical Scientist.
On February 11, 2023, Marianne De Backer , a director of Arrowhead Pharmaceuticals, Inc. (the “Company”), notified the Company of her decision to resign as a director, effective as of April 2, 2023.
Arrowhead Pharmaceuticals, Inc. (the “Company”) has appointed Patrick O’Brien, age 59, as Chief Operating Officer and General Counsel effective as of July 15, 2022.
the Board of Directors of Arrowhead Pharmaceuticals, Inc. (the “Company”) appointed Victoria Vakiener as an independent director of the Company effective May 2, 2022.
Effective August 23, 2021, James Hassard, the former Chief Commercial Officer of Arrowhead Pharmaceuticals, Inc. (the “Company”) is no longer with the Company.
Max materiality 0.95 · Median 0.70 · Most common event earnings